protein tyrosine phosphatase non-receptor type 11Genealiases: BPTP3 · CFC · JMML · METCDS · NS1 · PTP-1D
Q-omics provides the consensus-scored PTPN11 profile across patient tissues and cancer cell-line models. PTPN11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PTPN11 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, PTPN11 RNA expression shows 20,247 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where PTPN11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN11 survival associations across molecular data types. PTPN11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN11 RNA expression–survival associations across cancer types. High PTPN11 expression shows unfavorable associations in MESO, UVM, CESC and BLCA, but favorable associations in UCS and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for PTPN11 RNA expression.
This table summarizes PTPN11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PTPN11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN11 shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, KIRP, LIHC and COAD. The HNSC box plot shows higher PTPN11 RNA expression in tumor versus normal tissue (log2 FC = +0.752, t-test p < 0.001).
This table shows molecular features associated with PTPN11 in patient tissues and cancer cell lines. In patient samples, PTPN11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
